Log in

OTCMKTS:ADDXFAddex Therapeutics Stock Price, Forecast & News

0.00 (0.00 %)
(As of 05/25/2020 04:00 PM ET)
Today's Range
Now: $1.70
50-Day Range
MA: $1.70
52-Week Range
Now: $1.70
Average VolumeN/A
Market Capitalization$44.83 million
P/E RatioN/A
Dividend YieldN/A
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149 for epilepsy and undisclosed central nervous system disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Plan-les-Ouates, Switzerland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual SalesN/A



Market Cap$44.83 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ADDXF News and Ratings via Email

Sign-up to receive the latest news and ratings for ADDXF and its competitors with MarketBeat's FREE daily newsletter.

Addex Therapeutics (OTCMKTS:ADDXF) Frequently Asked Questions

How has Addex Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Addex Therapeutics' stock was trading at $1.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ADDXF stock has increased by 0.0% and is now trading at $1.70. View which stocks have been most impacted by Coronavirus.

Has Addex Therapeutics been receiving favorable news coverage?

Headlines about ADDXF stock have been trending very positive this week, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Addex Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutAddex Therapeutics.

Who are some of Addex Therapeutics' key competitors?

Who are Addex Therapeutics' key executives?

Addex Therapeutics' management team includes the following people:
  • Mr. Timothy Dyer, Co-Founder, CEO & Director (Age 51)
  • Dr. Roger G. Mills, Chief Medical Officer & Director (Age 62)
  • Dr. Jean-Philippe Rocher Ph.D., Head of Discovery - Chemistry (Age 60)
  • Dr. Robert Lütjens, Head of Discovery – Biology (Age 51)
  • Dr. Bruno Bournique, Head of Absorption, Distribution, Metabolism and Excretion (ADME) / Pharmacokinetics (PK)

What is Addex Therapeutics' stock symbol?

Addex Therapeutics trades on the OTCMKTS under the ticker symbol "ADDXF."

How do I buy shares of Addex Therapeutics?

Shares of ADDXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Addex Therapeutics' stock price today?

One share of ADDXF stock can currently be purchased for approximately $1.70.

How big of a company is Addex Therapeutics?

Addex Therapeutics has a market capitalization of $44.83 million. Addex Therapeutics employs 17 workers across the globe.

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.